# Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel Function

> **NCT04530383** · PHASE2 · RECRUITING · sponsor: **University of Kansas Medical Center** · enrollment: 30 (estimated)

## Conditions studied

- Cystic Fibrosis-related Diabetes
- Cystic Fibrosis

## Interventions

- **DRUG:** Metformin Hydrochloride

## Key facts

- **NCT ID:** NCT04530383
- **Lead sponsor:** University of Kansas Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-02-14
- **Primary completion:** 2027-12-30
- **Final completion:** 2028-07-15
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04530383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04530383, "Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel Function". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04530383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*